Abstract
Introduction: Europe contains 9% of the world population but has a 25% share of the global cancer burden. Up-to-date cancer statistics in Europe are key to cancer planning. Cancer incidence and mortality estimates for 25 major cancers are presented for the 40 countries in the four United Nations-defined areas of Europe and for Europe and the European Union (EU-28) for 2018.
Methods: Estimates of national incidence and mortality rates for 2018 were based on statistical models applied to the most recently published data, with predictions obtained from recent trends, where possible. The estimated rates in 2018 were applied to the 2018 population estimates to obtain the estimated numbers of new cancer cases and deaths in Europe in 2018.
Results: There were an estimated 3.91 million new cases of cancer (excluding non-melanoma skin cancer) and 1.93 million deaths from cancer in Europe in 2018. The most common cancer sites were cancers of the female breast (523,000 cases), followed by colorectal (500,000), lung (470,000) and prostate cancer (450,000). These four cancers represent half of the overall burden of cancer in Europe. The most common causes of death from cancer were cancers of the lung (388,000 deaths), colorectal (243,000), breast (138,000) and pancreatic cancer (128,000). In the EU-28, the estimated number of new cases of cancer was approximately 1.6 million in males and 1.4 million in females, with 790,000 men and 620,000 women dying from the disease in the same year.
Conclusion: The present estimates of the cancer burden in Europe alongside a description of the profiles of common cancers at the national and regional level provide a basis for establishing priorities for cancer control actions across Europe. The estimates presented here are based on the recorded data from 145 population-based cancer registries in Europe. Their long established role in planning and evaluating national cancer plans on the continent should not be undervalued.
Keywords: Cancer; Estimation; Europe; Incidence; Mortality.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26.PMID: 23485231
-
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers.Eur J Cancer. 2021 Nov;157:308-347. doi: 10.1016/j.ejca.2021.07.039. Epub 2021 Sep 21.PMID: 34560371 Free PMC article.
-
Estimates of cancer incidence and mortality in Europe in 1995.Eur J Cancer. 2002 Jan;38(1):99-166. doi: 10.1016/s0959-8049(01)00350-1.PMID: 11750846
-
Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.Lancet Oncol. 2022 Jun;23(6):719-728. doi: 10.1016/S1470-2045(22)00270-4. Epub 2022 May 9.PMID: 35550275 Review.
-
Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996.Lung Cancer. 1997 May;17(1):1-60. doi: 10.1016/s0169-5002(97)00648-x.PMID: 9194026 Review.
Cited by
-
Skin diseases in hospitalized geriatrics: a 9-year analysis from a University Dermatology Center in Germany.Arch Dermatol Res. 2022 Jul;314(5):427-437. doi: 10.1007/s00403-021-02244-9. Epub 2021 Jun 2.PMID: 34076756 Free PMC article.
-
Fertility-sparing treatment in early endometrial cancer: current state and future strategies.Obstet Gynecol Sci. 2020 Jul;63(4):417-431. doi: 10.5468/ogs.19169. Epub 2020 Jul 8.PMID: 32689770 Free PMC article.
-
Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.BJUI Compass. 2022 Jun 11;3(6):458-465. doi: 10.1002/bco2.169. eCollection 2022 Nov.PMID: 36267207 Free PMC article.
-
Experiences and perspectives of patients with advanced cancer regarding work resumption and work retention: a qualitative interview study.Support Care Cancer. 2022 Dec;30(12):9713-9721. doi: 10.1007/s00520-022-07436-1. Epub 2022 Nov 25.PMID: 36434411 Free PMC article.
-
Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.Medicine (Baltimore). 2020 Jul 2;99(27):e20944. doi: 10.1097/MD.0000000000020944.PMID: 32629699 Free PMC article.


